Pfizer, Sangamo Therapeutics

Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes
Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones.
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future of gene therapies.
Pfizer kills hemophilia gene therapy deal, imperiling Sangamo
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade. Sangamo added that it has now regained the rights to the therapy's development and would explore all options to advance the program,
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership
Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner Pfizer (PFE) decided not to proceed with further development of a new gene therapy to treat hemophilia A,
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal
Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing 50% in premarket
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, terminated its global collaboration and license agreement for giroctocogene fitelparvovec,
Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1
The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.
Pfizer: A Step-By-Step Strategy Before Earnings
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
FiercePharma1d
Pfizer, BMS and more ring in 2025 with fresh round of drug price increases: report
While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
BioPharma Dive1d
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Pfizer's 2025 Comeback: What's Driving Growth
Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...
Hosted on MSN18h
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...